LQDA
LiquidiaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings read-through improved: secondary follow-up coverage indicated Q1 revenue and EPS beat consensus, and at least two analysts reportedly raised targets to about $59-$60 after the print, which is more constructive than the stale packet median target of $45.7. The main bull argument is that YUTREPIA launch depth, prescriber expansion, and positive EBITDA are arriving faster than a typical small-cap biopharma commercialization curve.
Posture
Constructive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Commercial expectations are now higher after a strong Q1; sustaining launch growth at a much larger revenue base is harder, especially as SG&A rose materially with the commercial buildout [#8-K-2026-05-11].
Momentum
97
Value
41
Sentiment
49
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $56.00 · Bull $68.00 · Bear $38.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $45.67
Why
Momentum97 · Δ7d +0.8
Value41 · Δ7d +0.1
Sentiment49 · Δ7d +6.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+15.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
49
33% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+19.7
Why this grade
Composite grade A. Momentum 97.5 / Value 41.1 / Sentiment 48.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.22B
Beta
0.47
Shares Out
87M
P/E (TTM) · Derived
-36.2
P/S (TTM)
40.41
P/FCF (TTM) · Derived
-47.58
Rev YoY
+1121.7%
EPS YoY
+86.2%
Gross Margin
+89.1%
Op Margin
-155.0%
Net Debt
-
Current Ratio
2.20
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology